MicroGenDX
Focus: MicroGenDX is a publicly-traded diagnostics company specializing in molecular diagnostics and DNA sequencing technologies, operating at a mid-cap scale with 51-200 employees based in Lubbock, Texas. The company focuses on next-generation sequencing applications across niche therapeutic areas including wound care and urology.
Profile data last refreshed 35m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
1
Should You Work at MicroGenDX?
AI assessmentMicroGenDX presents a speculative opportunity in genomic diagnostics with public-market upside, but current hiring freeze, opaque financials, and underdeveloped pipeline make it a higher-risk career move for stability-focused professionals.
Why Work Here
- Public company status provides liquidity and potential equity upside, reducing pre-revenue startup risk
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Antimicrobial Skin & Wound Cleanser
Acute WoundNext-Generation DNA Sequencing
Penile ImplantationClinical Trials (1)
Help build intelligence for MicroGenDX
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.